However, the studies reporting PIK3CA [28–30] and AKT1 mutations [10, 20] in patients affected by lung cancer, and in particular in a subset with squamous cell carcinomas for which no targeted therapy is available yet, have suggested that these genes may represent relevant therapeutic targets for these patients [21, 31–33]. This evidence concerns the gene AKT1 and lung carcinoma.